Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05593614 · ClinicalTrials.gov registry record · Phase 2

Efficacy and Safety of ATX01 in Adult Patients With CIPN (Chemotherapy-induced Peripheral Neuropathy)

A Phase 2 study of Chemotherapy-induced Peripheral Neuropathy, sponsored by AlgoTherapeutix.

Active
Registry status
Phase 2
Development phase
276
Enrollment target
20
Study locations

NCT05593614 is a Phase 2 study of Chemotherapy-induced Peripheral Neuropathy that is active but no longer recruiting, run by AlgoTherapeutix. The registered enrollment target is 276 participants, above the 129-participant average among 29 other Chemotherapy-induced Peripheral Neuropathy trials with a reported enrollment target (114% higher). The trial reports 20 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05593614, a Phase 2 study of Chemotherapy-induced Peripheral Neuropathy, is active but no longer recruiting, sponsored by AlgoTherapeutix.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
276 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this clinical trial is to compare the efficacy of twice daily applications of ATX01 (10% \& 15%) versus placebo during a 12-week treatment period in treating chemotherapy-induced peripheral neuropathy (CIPN) in adult cancer survivor patients.

Conditions Studied

Chemotherapy-induced Peripheral Neuropathy

Interventions

  • DRUG Placebo
  • DRUG ATX01 10%
  • DRUG ATX01 15%

Study Locations (20)

Other

  • OLV Hospital Aalst: gastro-enterologie - Aalst
  • Universitair Ziekenhuis Antwerpen - Edegem
  • Universitair Ziekenhuis Gent (UZ Gent) - Ghent
  • UZ Leuven / Campus Pellenberg / Pain Center - Pellenberg
  • CHU UCL Namur - site Godinne - Yvoir
  • Clinitrial s.r.o. - Prague
  • Praglandia s.r.o. - Prague
  • Nemocnice Teplice - Teplice
  • Centre Hospitalier de la Côte Basque - Bayonne
  • Institute Bergonie - Bordeaux
  • CHU de Montpellier, Hôpital Saint Eloi - Montpellier
  • Groupe Hospitalier Paris Saint Joseph - Paris

Florida

  • South Lake Pain Institute - Clermont
  • MGM Medical Care Research & Rehab, LLC - Miami
  • Medsol Clinical Research Center, Inc - Port Charlotte
  • Knight Neurology - Clinical Research - Rockledge

Kansas

  • Neuroscience Research Center, LLC. - Overland Park

Maryland

  • The Center for Cancer and Blood Disorders (CCBD) - Bethesda

New York

  • University of Rochester Medical Center - Rochester

Texas

  • HD Research - Bellaire

Trial Details

FieldValue
Enrollment Target 276 participants
Start Date 2023-02-28
Est. Completion 2024-09
Phase Phase 2

Sponsor

AlgoTherapeutix

2 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05593614

The ClinicalTrials.gov registry entry for NCT05593614 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 276 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 129-participant average among 29 other Chemotherapy-induced Peripheral Neuropathy trials with a reported enrollment target (114% higher). The listed sponsor is AlgoTherapeutix, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Chemotherapy-induced Peripheral Neuropathy appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT05593614 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Other, Florida, Kansas.

Frequently Asked Questions

What is clinical trial NCT05593614 about?

NCT05593614 is a clinical study titled "Efficacy and Safety of ATX01 in Adult Patients With CIPN (Chemotherapy-induced Peripheral Neuropathy)". The purpose of this clinical trial is to compare the efficacy of twice daily applications of ATX01 (10% \& 15%) versus placebo during a 12-week treatment period in treating chemotherapy-induced peripheral neuropathy (CIPN) in adult cancer survivor patients.

What is the current status of trial NCT05593614?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 276 participants. The study started on 2023-02-28. Estimated completion is 2024-09.

What conditions does trial NCT05593614 study?

This clinical trial studies the following conditions: Chemotherapy-induced Peripheral Neuropathy.

What interventions are being tested in trial NCT05593614?

The interventions under investigation include: Placebo (DRUG), ATX01 10% (DRUG), ATX01 15% (DRUG).

Who is sponsoring clinical trial NCT05593614?

This trial is sponsored by AlgoTherapeutix, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05593614 being conducted?

This trial has 20 study locations across Florida, Kansas, Maryland, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Chemotherapy-induced Peripheral Neuropathy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Chemotherapy-induced Peripheral Neuropathy

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.